Market Place
Sourcing Support
Biogen in up to $1.8 bln deal as rare diseases take center stage
23 May 2024 //
REUTERS
FDA revises guidance on predicting Alzheimer`s drug benefits
12 Mar 2024 //
FIERCE BIOTECH
Biogen drops Alzheimer`s drug Aduhelm, ending a 17-year chapter
01 Feb 2024 //
REUTERS
Biogen comes out ahead in Aduhelm-related investor lawsuit
31 Mar 2023 //
FIERCE PHARMA
VA to cover Eisai`s new Alzheimer`s drug after declining to cover Aduhelm
14 Mar 2023 //
ENDPTS
Dunn with the FDA: head of agency`s neuroscience unit to depart
27 Feb 2023 //
FIERCE BIOTECH
FDA adds warning of `larger areas of bleeding` in brain to Aduhelm label
15 Feb 2023 //
ENDPTS
Biogen`s Biologic ADUHELM (Aducanumab) Receives Approval in the U.S.
08 Feb 2023 //
FDA
Eisai files for approval of Alzheimer`s drug in Europe
11 Jan 2023 //
REUTERS
Eisai taps its native tongue for new Alzheimer`s drug Leqembi
09 Jan 2023 //
FIERCE PHARMA
Congressional inquiry into `highly atypical` FDA-Biogen ties ends damning report
03 Jan 2023 //
ENDPTS
Biogen-FDA`s unusual Aduhelm coordination revealed: report
30 Dec 2022 //
FIERCE PHARMA
Eisai, Biogen`s new Alzheimer`s drug should be priced below Aduhelm
24 Dec 2022 //
REUTERS
ICER on Alzheimer`s: lecanemab should be priced lower than Aduhelm
22 Dec 2022 //
ENDPTS
Ahead of lecanemab decision, Alzheimer`s petition CMS to reverse coverage policy
20 Dec 2022 //
ENDPTS
Lilly’s Alzheimer’s drug bests Aduhelm in plaque clearance study
02 Dec 2022 //
BIOPHARMADIVE
Winner crowned in Alzheimer`s contest between Aduhelm and Lilly
01 Dec 2022 //
FIERCEBIOTECH
First virtual clinical trial examines two promising Alzheimer’s drugs
04 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
FDA delays decision on Biogen’s ALS hope tofersen
18 Oct 2022 //
PHARMAPHORUM
Biogen Officers Under Investigation for Possible False Statements About Aduhelm
13 Oct 2022 //
PRNEWSWIRE
Eisai inaugurates new US HQ as key Alzheimer`s decision nears
20 Aug 2022 //
FIERCEPHARMA
Amid Aduhelm woes, Biogen moves to pare back office space
10 Aug 2022 //
STAT NEWS
Biogen strikes back at investor lawsuit on Aduhelm launch flop
30 Jul 2022 //
FIERCEPHARMA
Biogen says its $223M inventory of Aduhelm is basically worthless
21 Jul 2022 //
ENDPTS
Biogen`s Quarterly Report Was `Fine` — Here`s Why Shares Toppled
20 Jul 2022 //
INVESTORS
Biogen yanks its Aduhelm application in Canada
11 Jun 2022 //
ENDPTS
Medicare doesn`t reduce its 2022 premium hike
31 May 2022 //
ENDPTS
Biogen`s Aduhelm can`t catch a break even in Alzheimer`s trials
17 May 2022 //
FIERCEPHARMA
Eisai completes accelerated filing for Aduhelm follow up
10 May 2022 //
FIERCEBIOTECH
Biogen shoves Aduhelm to the side. It`s time for lecanemab
04 May 2022 //
FIERCEBIOTECH
Next Biogen CEO`s most-prized expertise? BD, say investors
04 May 2022 //
FIERCEPHARMA
Biogen Walks Away From Alzheimer’s Flop With CEO Set to Depart
04 May 2022 //
BLOOMBERGQUINT
Biogen`s `Life After Aduhelm` Doesn`t Include CEO Michel Vounatsos
03 May 2022 //
INVESTORS
Biogen board slashes CEO’s bonus as Aduhelm sales and overall business struggle
30 Apr 2022 //
STATNEWS
Biogen`s Aducanumab Receives Supplemental Approval in U.S.
29 Apr 2022 //
FDA
As US launch falters, Biogen ditches Aduhelm application in Europe
23 Apr 2022 //
FIERCEPHARMA
The FDA approved a new drug to treat Alzheimer`s
18 Apr 2022 //
ET HEALTH
CMS keeps strict limits on coverage of Biogen`s Aduhelm
08 Apr 2022 //
FIERCEPHARMA
Alzheimer`s expert picks apart Biogen`s Aduhelm manuscript
04 Apr 2022 //
ENDPTS
Biogen Submits Final Protocol for ADUHELM Phase 4 ENVISION Trial to FDA
30 Mar 2022 //
GLOBENEWSWIRE
FDA investigating how accelerated approval drugs marketed DTC
30 Mar 2022 //
FIERCEPHARMA
Long-Term P 3 Data Show ADUHELM Continues to Reduce Underlying Pathologies
16 Mar 2022 //
GLOBENEWSWIRE
Eisai to receive royalties instead of profits from Alzheimer`s drug Aduhelm
15 Mar 2022 //
REUTERS
Biogen, struggling to sell Alzheimer`s drug, begins layoffs to save money
04 Mar 2022 //
BIOPHARMADIVE
3 more deaths among Aduhelm patients add to safety concerns
17 Feb 2022 //
FIERCEPHARMA
Biogen, Eisai strike back against CMS` stifling Aduhelm coverage proposal
11 Feb 2022 //
FIERCEPHARMA
Biogen slams coverage proposal for amyloid-targeted Alzheimer`s drugs
10 Feb 2022 //
ENDPTS
More Federal regulators launch probe into Biogen’s Aduhelm
07 Feb 2022 //
HEALTHCAREAFRICA
Lilly slacks off FDA submission of Alzheimer’s drug post CMS decision on Aduhelm
07 Feb 2022 //
HEALTHCAREAFRICA
Biogen says U.S. FTC, SEC probing Alzheimer`s disease drug
05 Feb 2022 //
REUTERS
Eli Lilly pushes back timeline for Alzheimer`s drug application
04 Feb 2022 //
REUTERS
Biogen`s Aduhelm pulls in only $3M in 2021
03 Feb 2022 //
FIERCEPHARMA
CMS` Aduhelm decision could bleed through to rivals
01 Feb 2022 //
FIERCEPHARMA
Medicare received majority of comments iffy on Biogen`s Aduhelm
01 Feb 2022 //
FIERCEPHARMA
Two biogen board members depart amid Aduhelm mess
01 Feb 2022 //
FIERCEPHARMA
Biogen expands Aduhelm confirmatory trial
28 Jan 2022 //
FIERCEPHARMA
What lured Hal Barron away?; and more
22 Jan 2022 //
ENDPTS
Biogen said to make buyout list, or is a target?
14 Jan 2022 //
FIERCEPHARMA
Biogen wants Aduhelm supporters to make their voices heard
14 Jan 2022 //
FIERCEPHARMA
CMS to restrict coverage of Biogen`s Aduhelm to only clinical trials
11 Jan 2022 //
ENDPTS
